Dan Shelly

About Dan Shelly

I am currently the Chief Business Development Officer and member of the Executive Leadership Team for PolTREG where I am responsible for advancing next generation T-regulatory cell therapies for Autoimmune disease including CAR-Tregs, TCR-Tregs, and Ag-specific Tregs for T1D, MS, ALS, and other AI diseases. PolTREG has completed construction on one of the largest, state of the art, cGMP manufacturing facilities in Europe (See https://poltreg.com/about-us/#our-facality).At Prescient, he was responsible for advancing the development of a next generation Chimeric Antigen Receptor T and or NK Cell therapy technology, called OmniCAR, along with small molecule targeted therapies. Prior to Prescient, he was Director of Global Business Development and Strategic Partnerships for the Global non-profit organization PATH where he was involved in the identification of new and innovative partnerships for vaccine and therapeutics development applicable to low and middle income countries. A BD and Licensing Leader with outstanding relationship building, clinical asset and technology evaluation, innovation, commercialization, and deal closing experience. Clinical asset prospecting, due diligence, agreements, valuation (rNPV), licensing, acquisitions, market analysis and alliance management of vaccines, advanced therapeutics (cell and gene therapies), and traditional biologics. At Albumedix, I was responsible for asset in-licensing, alliances, and out-licensing, search/evaluation of clinical assets and strategic review. I led initiatives around the applications of our core technologies in stem cell therapy, gene therapy, and vaccines. At Meridian, I was responsible for biologics manufacturing leads, proposal writing, and contract negotiations. I negotiated global exclusive license for the Parvovirus B19 vaccine from NIH and was instrumental in the manufacture, IND approval, and Phase I study of this vaccine. I led development and commercialization of the RSV Memphis 37 clinical challenge virus used in over 6 human trials.I have been an adjunct professor in the Master’s in Clinical Drug Development program at the UC College of Pharmacy since 2004. I teach Biologics Discovery and Biotech Business Management. I was awarded the prestigious “Outstanding Adjunct Faculty Award” for vital contributions to the University Teaching mission for 20••••19. As a postdoc I received the APS Fellowship in Physiological Genomics (only 2 given annually) and a NIH NRSA. Vaccines, gene therapy, cell therapy, oncology, autoimmune, and immunomodulation.

Experience

1. Board of Directors - Biosolutions Designs

   Biosolution Designs

   Jan 2021 — Present · Cincinnati, OH, US

Education

• William & Mary

  MA, Physiology

  1991 — 1994

• University of Cincinnati College of Medicine

  Post Doctoral Fellow, Molecular Physiology

  1997 — 2001

• Florida State University

  PhD, Molecular Physiology

  1993 — 1997

• Lehigh University

  BS, Biology

  1987 — 1991

• University of Cincinnati Carl H. Lindner College of Business

  MBA, Innovation

  2000 — 2002

Skills

• Protein Chemistry
• Antibodies
• Strategy
• Strategic Planning
• Competitive Analysis
• Contract Negotiation
• Vaccines
• Business Strategy
• Drug Delivery
• Valuation
• Life Sciences
• Leadership
• Pharmaceuticals
• Clinical Development
• Strategic Partnerships
• Glp
• Problem Solving
• Regulatory Affairs
• Lifesciences
• Controled Release
• Clinical Trials
• Oncology
• Biologics
• Immunology
• Mergers & Acquisitions
• Business Development
• Genomics
• Infectious Diseases
• Cgmp
• Medical Devices
• Clinical Research
• Cross-Functional Team Leadership
• Biotechnology
• Mentoring
• Half-Life Extension
• Immunoassays
• Gmp
• Cell
• Key Account Management
• Drug Development